Archive for the ‘Genetic Testing’ Category

One of the goals of COVID-19 research is understanding why some people develop mild or moderate cases while others experience life-threatening illness. Researchers have made progress in understanding some of the factors that make a difference, including obesity and underlying health conditions like diabetes and heart disease.

Recently, an ongoing study by European scientists has suggested one more potential factor to consider: blood type. Preliminary results of this investigation (which have not yet been peer reviewed) were shared on June 2 on the preprint service MedRxiv.

The researchers scrutinized blood samples from 1,610 hospitalized patients in Italy and Spain with the disease, as well as a 2,205 healthy people in a control group. Their analysis identified variations at two distinct areas on the genome (the complete set of human DNA, including all genes) that were associated with greater risk for severe reactions toSARS-CoV-2, the virus that causes COVID-19, including respiratory failure.

One of these areas on the genome is related to blood types. The researchers found that type A blood was associated with a 50 percent increase in risk that a patient would become extremely ill with COVID-19 and need supplemental oxygen or a ventilator.

This conclusion supports findings from early research done in China, which appeared March 27 in MedRxiv. This gave the researchers more confidence in the associations, says study coauthor Andre Franke, PhD, professor of molecular medicine at the Institute of Clinical Molecular Biology at University Hospital Schleswig-Holstein in Kiel, Germany.

Researchers on another ongoing study, by genetic testing firm 23andMe, released preliminary data on June 8 suggesting that type O blood is protective against COVID-19. The researchers found that people with type O blood are between 9 and 18 percent less likely to test positive for COVID-19 than other blood types.

The 23andMe study is still recruiting subjects, but already has 750,000 participants and is likely to come out with more data regarding genetic associations and COVID-19.

RELATED: The New Normal: What We Know About the Coronavirus So Far and How We Got Here

Dr. Franke hopes to build on the findings about type A blood withmore targeted research, he says, especially because there are 36 known human blood groups. In addition to the four main types A, B, AB, and O there is also a deeper classification system that includes different combinations of antigens (molecules on the surface of every red blood cell) and other substances.

There are other types of diseases where blood types and blood groups affect a persons susceptibility. For example, people who lack a specific type of antigen, called a Duffy antigen, have a higher resistance to malaria.

In terms of why a variant like the gene related to blood type would have significance for COVID-19, Franke says there are three possible hypotheses.

One is that the genetic variant itself contributes to the so-called cytokine storm, in which a persons immune system goes into overdrive in response to the novel coronavirus threat, releasing large amounts of pro-inflammatory substances called cytokines. An excess of cytokines can damage healthy tissues.

The second hypothesis is that the genetic variant causes more coagulation (blood clotting) in response to the coronavirus an already observed result of disease progression.

The third theory is that both of these reactions are occurring simultaneously.

There may be other issues at play here, but given the way we know COVID-19 works, these seem the most likely reasons, Franke says. Next steps are to dig deeper into the blood groups system and see if we can pinpoint actual disease causes.

RELATED: What People With Heart Disease Need to Know About COVID-19

What should you do in response to these studies, considering you can't change your blood type? Nothing yet. Theres no need to get to a doctor if youre type A, and on the flip side, theres no reason to relax your precautions against coronavirus transmission like social distancing and hand-washing if youre type O.

Keep in mind these are preliminary results and more research needs to be done to understand how genetic variations truly affect COVID-19.

More than anything, its a nod toward how much we have left to learn about the way this virus operates, and how genetic variants may affect why some people end up in the ICU and others have milder symptoms or even none at all, says Priya Duggal, PhD, director of the genetic epidemiology program at Johns Hopkins Bloomberg School of Public Health in Baltimore.

If we can find genes that may explain some of the risk or protection from this infection, it will give us insight into the mechanism of disease, she says.

If genetics studies help us better understand how COVID-19 affects the body, they may eventually help lead to treatments.

This genetic study is hopefully the first of many that will help us to elucidate disease mechanism, susceptibility to infection, and maybe even antibody response, says Dr. Duggal. That could provide potential targets for therapeutics. We have a lot to learn from this point, but were gaining more insight with every study.

Continued here:
Blood Type and COVID-19 Risk - Everyday Health

New Jersey, United States,- A new study was presented by Verified Market Research offering a complete analysis of the Direct-To-Consumer (DTC) Genetic Testing Market where the user can benefit from the complete market research report with all the useful information required on this market. This is a final report, covering the current impact of COVID-19 on the market. The coronavirus pandemic (COVID-19) has affected all aspects of life around the world. This has resulted in several changes in market conditions. The rapidly changing market scenario and the initial and future impact assessment are addressed in the report. The report examines all major aspects of the market with expert opinion on the current state of the market as well as historical data. This market report is a detailed study of growth, investment opportunities, market statistics, analysis of growing competition, key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, main regions, demand and developments.

The Direct-To-Consumer (DTC) Genetic Testing Market Report provides a detailed analysis of the global market size, regional and national market size, segment growth, market share, competitive landscape, sales analysis, the impact of players in national and global markets, value chain optimization, business regulations, recent developments, opportunity analysis, strategic analysis of market growth, product launches and technological innovations.

Get | Sample Copy of the Direct-To-Consumer (DTC) Genetic Testing Market Report with Latest Industry Trends @ https://www.verifiedmarketresearch.com/download-sample/?rid=25584&utm_source=PFS&utm_medium=002

Major Players Covered in this Report are:

Direct-To-Consumer (DTC) Genetic Testing Market Segmentation

This market has been divided into types, applications and regions. The growth of each segment provides a precise calculation and forecast of sales by type and application, in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting qualified niche markets. . Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, Asia-Pacific, the Middle East and Africa and Latin America. Research analysts understand competitive forces and provide competitive analysis for each competitor separately.

By Types:

YYYY

By Applications:

ZZZZ

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=25584&utm_source=PFS&utm_medium=002

Direct-To-Consumer (DTC) Genetic Testing Market Regions and Countries Level Analysis

The regional analysis is a very complete part of this report. This segmentation highlights Direct-To-Consumer (DTC) Genetic Testing sales at regional and national level. These data provide a detailed and precise analysis of the volume by country and an analysis of the market size by region of the world market.

The report provides an in-depth assessment of growth and other aspects of the market in key countries such as the United States, Canada, Mexico, Germany, France, the United Kingdom, Russia, the Italy, China, Japan, South Korea, India, Australia, Brazil and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total (financial) revenue, market potential, global presence, sales Direct-To-Consumer (DTC) Genetic Testing and the income generated, market share, prices, production sites and facilities, products offered and strategies adopted. This study provides Direct-To-Consumer (DTC) Genetic Testing sales, revenues and market shares for each actor covered in this report for a period between 2016 and 2020.

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Direct-To-Consumer-DTC-Genetic-Testing-Market/?utm_source=PFS&utm_medium=002

Why Choose Us:

Table of Contents

1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Diaphragm Pump Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Direct-To-Consumer (DTC) Genetic Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Disc Prostheses Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Here is the original post:
Direct-To-Consumer (DTC) Genetic Testing Market Key Players, SWOT Analysis, Dynamics, Drivers, Key Indicators and Forecast to 2026 - Owned

The Global Direct-To-Consumer (DTC) Genetic Testing Market was $1.1 Bn in 2019, and it is expected to reach $2.7 Bn by 2026.

This press release was orginally distributed by SBWire

Kolkata, West Bengal -- (SBWIRE) -- 06/18/2020 -- According to a new market research report published by sheer analytics and insights, "The Global Direct-To-Consumer (DTC) Genetic Testing Market was $1.1 Bn in 2019, and it is expected to reach $2.7 Bn by 2026. It is eventually growing at a commendable high compound of annual growth rate CAGR of 13.5% between 2020-2026. However, the current pandemic of COVID-19 might make a slight difference in the growth rate in the present year. The Direct-To-Consumer (DTC) Genetic Testing Market are majorly driven by some of the factors such as rising genetic disorders globally. Increasing genetic diseases such as breast cancer, achondroplasia, colorectal cancer and other diseases is expected to propel the market growth rapidly. Further, high quality DTC genetic testing can significantly reduce the mortality rates of cancer patients. This significant benefit of DTC genetic testing along with rising public awareness, increasing income level in emerging economies, and rising demand for service personalization may propel the Direct-To-Consumer (DTC) Genetic Testing Market in the forecast period.

Direct-To-Consumer (DTC) Genetic Testing Market is expected to provide sustainable growth opportunities during the forecast period from 2020 to 2026. This latest industry research study analyzes the Direct-To-Consumer (DTC) Genetic Testing market by various product segments, applications, regions and countries while assessing regional performances of numerous leading market participants.

Browse Full report on Global Direct-To-Consumer (DTC) Genetic Testing Market report at https://www.sheeranalyticsandinsights.com/market-report-research/direct-to-consumer-dtc-genetic-testing-market-21

The report titled "Direct-To-Consumer (DTC) Genetic Testing Market - Global Trends, Market Share, Industry Size, Growth, Opportunities, and Forecast 2020 2026" offers a holistic view of the Direct-To-Consumer (DTC) Genetic Testing industry encompassing numerous stakeholders including raw material suppliers, providers, distributors, consumers and government agencies, among others. Furthermore, the report includes detailed quantitative and qualitative analysis of the global Direct-To-Consumer (DTC) Genetic Testing market considering market history, product development, regional dynamics, competitive landscape, and key success factors (KSFs) in the industry.

The report includes a deep-dive analysis of key countries including the U.S., Canada, the U.K., Germany, France, China, Japan, India, Australia, Mexico, Brazil and South Africa, among others. Thereby, the report identifies unique growth opportunities across the world based on trends occurring in various developed and developing economies.

Global Direct-To-Consumer (DTC) Genetic Testing Market report summarizes the positive growth rate in upcoming years, and market size with competitive analysis. Our experts have analyzed the historical data to compare with the current market scenario to calculate the market growth in the coming years. The study provides an exhaustive report that includes an executive summary, scope, and forecast of the market.

Key Questions Answered by Direct-To-Consumer (DTC) Genetic Testing Market Report

Product popularity and adoption based on various country-level dynamicsRegional presence and product development for leading market participantsMarket forecasts and trend analysis based on ongoing investments and economic growth in key countriesCompetitive landscape based on revenue, product offerings, years of presence, number of employees and market concentration, among others

Number of employees and market concentration, among others

Browse the full report at https://www.sheeranalyticsandinsights.com/market-report-research/direct-to-consumer-dtc-genetic-testing-market-21

List of Key Companies:

Ancestry,Color Genomics,Easy DNA,FamilytreeDNA (Gene By Gene),Full Genome Corporation,Helix OpCo LLC,Identigene,Karmagenes,Living DNA,Mapmygenome,MyHeritage,Pathway genomics,Genesis Healthcare,23andMe,Myriad Genetics, andQuest Diagnostics.

The Global Direct-To-Consumer (DTC) Genetic Testing Market Has Been Segmented into:

By Test Type

Carrier TestingNutrigenomic TestingAncestry & Relationship TestingPredictive TestingOthers

By Technology

Single Nucleotide Polymorphism (SNP) ChipsWhole Genome Sequencing (WGS)Targeted Analysis

By Distribution Channel

Online PlatformsOver the Counter

By Geography Type

North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa

To know more about this study, request a free sample report @ https://www.sheeranalyticsandinsights.com/request-sample/direct-to-consumer-dtc-genetic-testing-market-21

About Us:

Sheer Analytics and Insights as firm is created to balance between client requirements without compromising the core values of Market research in terms of quality, factual correctness, market awareness and analysis. SAI goes back to the root of Market Research in terms of TAM (Total Available Market) and PAM (Potential Available Market) and assess the same quantifying all Push and Pull factors.

Related Reports:

Disposable Protective Clothing Market: https://www.sheeranalyticsandinsights.com/market-report-research/Disposable-protective-clothing-market-21

CRISPR Technology Market: https://www.sheeranalyticsandinsights.com/market-report-research/global-crispr-technology-market-report-21

Smart Grid Market: https://www.sheeranalyticsandinsights.com/market-report-research/global-smart-grid-market-report-21

For more information on this press release visit: http://www.sbwire.com/press-releases/direct-to-consumer-dtc-genetic-testing-market-135-cagr-2020-to-2026-global-industry-size-share-growth-trends-and-forecast-1294473.htm

Visit link:
Direct-to-Consumer (DTC) Genetic Testing Market (13.5% CAGR) 2020 to 2026: Global Industry Size, Share, Growth, Trends and Forecast - Press Release -...

HealthCoronavirusUniversity researchers are asking for people who have used home DNA testing kits to share their results in a bid to see if there is any genetic reason why some people suffer from Coronavirus worse than others.

Monday, 15th June 2020, 12:01 am

Data from popular home genetic-testing kits could help scientists shed light on why some people who catch coronavirus have no symptoms while others become very ill.

Researchers are asking people who have used DNA testing services such as Ancestry DNA, FTDNA and 23andMe to gain ancestry or health insights to join a study that aims to identify key genes involved in the bodys response to the infection.

Understanding the effect genes have on susceptibility to Covid-19 could aid efforts to tackle the pandemic, and help combat future disease outbreaks, researchers say.

Sign up to our public interest bulletins - get the latest news on the Coronavirus

Sign up to our public interest bulletins - get the latest news on the Coronavirus

More than 30 million people worldwide have used genetic testing services. Researchers are urging them to share their DNA data to help speed up discoveries that could help fight the virus.

By providing these data, volunteers will help the team avoid the costly, time-consuming task of collecting the hundreds of thousands of DNA samples that would otherwise be needed to map the genes involved.

Volunteers who have not used these services will also be able to provide the project with DNA, once current lockdown restrictions have been eased.

The team aims to identify genes that influence the risk of developing Covid-19 and those that affect disease severity, by comparing volunteers symptoms or lack of them with their DNA.

Those taking part in the University of Edinburgh study called Coronagenes will complete online questionnaires about their health, lifestyle and any symptoms they have experienced, such as fever or a persistent cough.

Updating the survey before, during and after an infection will help scientists detect any patterns that might indicate how the virus progresses.

Researchers also aim to analyse the long-term health consequences of infection and self-isolation.

The study is supported by the Medical Research Council, Biotechnology and Biological Science Research Council, Health Data Research UK and Wellcome Trust.

Jim Wilson, Professor of Human Genetics at the University of Edinburgh, who is co-leading the study, said: Some people suffer no ill effects from coronavirus infection, yet others require intensive care. We need to identify the genes causing this susceptibility, so we can understand the biology of the virus and hence develop better drugs to fight it.

Albert Tenesa, Professor of Quantitative Genetics at the University of Edinburgh, also co-leading, said: Time is of the essence. To identify the genes that explain why some people get very sick from coronavirus and others dont, we need the solidarity of a large proportion of people from different countries who can share their DNA testing results with us. In this case, size really matters.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.In order for us to continue to provide high quality and trusted local news on this free-to-read site, I am asking you to also please purchase a copy of our newspaper.

Our journalists are highly trained and our content is independently regulated by IPSO to some of the most rigorous standards in the world. But being your eyes and ears comes at a price. So we need your support more than ever to buy our newspapers during this crisis.

With the coronavirus lockdown having a major impact on many of our local valued advertisers - and consequently the advertising that we receive - we are more reliant than ever on you helping us to provide you with news and information by buying a copy of our newspaper.

Read the rest here:
Home DNA kit test results to be used in fight against Coronavirus - The Scotsman

Geneticist Dr. Kat Arney explores the stories of two women one a scientist fascinated by dancing mice, the other a seamstress with a deadly family legacy who made significant contributions to our understanding of cancer as a disease driven by genetic changes. Yet while their work paved the way for lifesaving screening programs for families, it was used by some as justification for eugenics the idea of removing genetic defectives from the population.

Born in Minnesota in 1879, Maud Slye was a cancer pathologist who dedicated her career to studying patterns of cancer inheritance in more than 150,000 mice. But as well as being a dedicated scientist (as well as a part-time poet), she was also wedded to eugenic ideas, suggesting that If we had records for human beings comparable to those for mice, we could stamp out cancer in a generation. At present, we take no account at all of the laws of heredity in the making of human young. Do not worry about romance. Romance will take care of itself. But knowledge can be applied even to romance.

While her ideas were controversial, Slyes work earned her a gold medal from the American Medical Society in 1914 and from the American Radiological Association in 1922. She was also awarded the Ricketts Prize from the University of Chicago in 1915 and an honorary doctorate from Brown University in 1937. She was even nominated for a Nobel prize in 1923.

Over the decades since Slyes death in 1954, weve come to understand that the hereditary aspects of cancer susceptibility are much more complicated than she originally suggested, although her work was vital in establishing inherited gene variations as an essential thread of cancer research.

Running parallel to Slyes work in mice was the research carried out by Aldred Warthin, a doctor working at the University of Michigan in Ann Arbor. One day in 1895, a chance meeting between Warthin and a local seamstress, Pauline Gross, set the two of them off on a 25-year-long quest to understand why so many members of Paulines family had died from cancer at a young age.

Pauline spent years compiling detailed family histories, enabling Warthin to trace the pattern of inheritance through Family G, as it became known. Like Slye, Warthin was a fan of eugenic ideas, describing Paulines family as an example of progressive degenerative inheritance the running-out of a family line through the gradual development of an inferior stock.

He was also quoted as saying in a 1922 lecture: Today it is recognized that all men are not born equal. We are not equal so far as the value of our bodily cells is concerned.

Perhaps as a direct result of growing public concern about eugenics, Warthins work fell out of favor. Paulines detailed genealogy lay undisturbed in a closet in the university until the 1960s, when American doctor Henry Lynch and social worker Anne Krush rediscovered her work and continued extending and investigating Family G.

Nearly a decade on from that first meeting between Pauline and Warthin, researchers finally pinned down the underlying genetic cause of this deadly legacy: an inherited variant of the MSH2 gene, which normally repairs mismatched DNA strands. Today, members of Family G and others around the world carrying dangerous variants in mismatch repair genes can undergo genetic testing, with a range of preventative and screening options available.

The story of Pauline and Family G, and the impact that their genetic legacy has had on the family down the generations, is beautifully told in the book Daughter of Family G, a memoir by Ami McKay.

Full transcript, links and references available online atGeneticsUnzipped.com

Genetics Unzippedis the podcast from the UKGenetics Society,presented by award-winning science communicator and biologistKat Arneyand produced byFirst Create the Media.Follow Kat on Twitter@Kat_Arney,Genetics Unzipped@geneticsunzip,and the Genetics Society at@GenSocUK

Listen to Genetics Unzipped onApple Podcasts(iTunes)Google Play,Spotify,orwherever you get your podcasts

Read more:
Podcast: The dark connection between cancer research and the eugenics movement - Genetic Literacy Project

Many factors like age and comorbidities have been studied to help us better understand Covid-19 and peoples susceptibility to its severity and now your blood type could be another factor that could influence your interaction with the coronavirus.

Private genetic testing company 23andME from the US have released some preliminary data from their ongoing genetic study on Covid-19, which they launched on 6 April.

It aims to find out if the ABO blood group can play a direct role in infections by serving as a receptor, or coreceptor for microorganisms, parasites, and viruses.

READ: Top WHO official backtracks on comments that asymptomatic spread of Covid-19 virus is 'rare'

From the data of 750 000 participants so far mostly customers from their existing database they have gleaned that type O blood appears to be more protective against contracting the virus and severe symptoms than other blood types.

People with this blood type appear to be 9 to 18% less likely to test positive for Covid-19. They created another sample set limited to only those with high exposure to the virus like medical practitioners and essential workers and found those with type O blood to be 13 to 26% less likely to contract the virus.

They add that their data holds even when taking into account other factors like age, sex, body mass index, ethnicity, and comorbidities.

ALSO READ: Are people with blood type A more vulnerable to contracting the new coronavirus?

While one study from Columbia University which hasnt been peer-reviewed yet did demonstrate that only O-positive blood types seem to show resilience to Covid-19. 23andMes results dont indicate any difference between rhesus positive and negative blood types.

But is any blood type more susceptible to the virus? The preliminary data did show that most people who tested positive had type AB blood, but the difference compared to other blood types was statistically inconsequential.

There have been more studies focusing on the link between blood types and the coronavirus. A joint limited study from Chinese universities involving 2 173 patients found similar results regarding blood type O, and found that type A blood group was most susceptible. Another study from Europe that looked at Spanish and Italian patients also found blood type O to be more protective, and that A-positive people had a higher risk.

Both studies still need to be peer-reviewed.

SEE: Covid-19 patients with high blood pressure face higher risk of death, study says

The 23andMe study, however, is still ongoing, and they are currently looking for more US-residing participants outside of their customer database that have tested positive for Covid-19. In return, they will get free access to the companys genetic reports.

The study and recruitment are ongoing, with the hope that we can use our research platform to better understand differences in how people respond to the virus. Ultimately, we hope to publish our research findings in order to provide more insight into Covid-19 for the scientific community.

Image credit: Pixabay

View post:
One blood type seems to be more resistant against Covid-19 - Health24

Researchers say that very few people with autism are undergoing the genetic testing they should. (Dreamstime/TNS)

It is widely recommended that individuals with autism receive a battery of genetic tests, but new research finds strikingly few people on the spectrum partaking.

Just 3 percent of those with autism have received both chromosomal microarray and fragile X testing, according to findings from a study published recently in the journal JAMA Psychiatry.

The American Academy of Pediatrics, the American College of Medical Genetics and the American Academy of Child and Adolescent Psychiatry all recommend both assessments in order to determine more precisely what might underlie an individuals symptoms and point to treatment options, the researchers said.

Advertisement - Continue Reading Below

The study looked at medical records and self-reported information from 1,280 people with autism ranging in age from 1 to 68 between 2013 and 2019. More than 16 percent of the participants said they had received some variety of genetic testing, with 13 percent having undergone fragile X testing and 4.5 percent receiving chromosomal microarray testing. But, the researchers found that only a small number of people were taking both of the recommended tests.

I had the impression that the frequency of recommended genetic testing was not going to be very high based on the patients I encounter clinically, but 3 percent is actually lower than I thought it would be, said Daniel Moreno De Luca, an assistant professor of psychiatry and human behavior at Brown University who worked on the paper.

The study found that genetic testing is more common for those diagnosed in recent years. Among individuals diagnosed with autism between 2010 and 2014, nearly 10 percent said they had received chromosomal microarray testing, which is a more modern offering. But, adults with autism were unlikely to have had any genetic testing.

Researchers behind the study said their findings highlight a disconnect between research and professional recommendations and whats happening in clinical practice.

This paper is really about how you implement clinical genetic tests in the clinical diagnostic setting, said Eric Morrow, an associate professor of biology at Brown and an author of the study. There is rapid progress from research, and then theres the doctor and health systems that need to translate that to clinical practice.

See more here:
Despite Recommendations, Genetic Testing Rare Among Those With Autism - Disability Scoop

Progenity, a molecular diagnostics testing lab, has amended its initial public offering filing and now aims to raise as much as $122.6 million through the sale of more than 7 million shares of its common stock.

The Ann Arbor, Michigan-based firm offers noninvasive prenatal tests for monogenic disease and chromosomal aneuploidies. It also carries a test for genetic diseases that parents can pass to their children.

Progenity initially filed in late May to go public, said it expects to float its shares on the Nasdaq at between $14 and $16 per share under the ticker symbol PROG. The underwriters of the planned offering Piper Sandler, Wells Fargo Securities, Robert W. Baird, Raymond James, and BTIG will also be granted a 30-day option to purchase an additional 1,000,000 shares at the IPO price.

Progenity is also redeveloping its proteomics-based preeclampsia rule-out test, and a platform for gastrointestinal (GI) disorders that uses a localizable, ingestible capsule to obtain a GI tract sample for diagnostic analysis or to deliver a therapeutic payload.

The molecular diagnostics testing lab said it expects to net approximately $103.0 million from the IPO, assuming a $15 per share offering price and full exercise of the underwriters' option. Progenity said it will use about $60 million to $65 million to support its operations, $9 million to $10 million to invest in its molecular testing R&D programs, and around $13 million to $15 million for its GI disorder platform.

The company also owes about $33 million to settle allegations of misconduct by three major insurance companies, it noted in the SEC filing.

Progenity recently agreed to pay millions to insurers Cigna, Aetna, UnitedHealthCare under settlement agreements related to allegations over undisclosed past business practices. Specifically, Progenity would pay Cigna $12 million on behalf of Avero, of which $2.5 million remains outstanding; Aetna $15 million, of which $7.5 million remains unpaid; and United HealthCare $30 million, with $23 million remaining to be paid.

Progenity also recently agreed to pay $49 million over a five-year period to resolve criminal and civil charges filed by the U.S. Department of Justice and the State of New York over discontinued billing practices for its NIPT and microdeletion tests, as well as alleged kickbacks or inducements made to physicians and patients. In the SEC filing, however, Progenity noted it had accrued $49 million as of March 31 to cover the potential settlement.

Natera on Wednesday sued Progenity, alleging that the firm's noninvasive prenatal test infringes six of its patents. The San Carlos, Cali-based genetic testing firm is seeking injunctive relief, monetary damages, court expenses, and a jury trial.

As of March 31, Progenity had $11.6 million in cash and cash equivalents.

This story first appeared in our sister publication, Genomeweb.

Original post:
Progenity eyes $122.6M in amended IPO - ModernHealthcare.com

According to the World Health Organisation, breast cancer is the most frequently occurring cancer in women, affecting more than 21 lakh women every year. Breast cancer and ovarian cancer is determined by mutations in a prominent gene present in the body known as the Breast Cancer Gene (BRCA). The BRCA genes are not only present in women but men too.

Moreover, previous studies have shown that mutations (change in the structure) in the BRCA genes in men can increase the risk of breast cancer, prostate cancer, and other cancers. Recently, the Food and Drug Administration (FDA) of the US, approved two new drugs, rucaparib and olaparib, specifically for men with BRCA-positive prostate cancer that has stopped responding to other treatment.

Representational image. Pixabay

What is BRCA?

Each person has a DNA which forms the human body and helps it in functioning. Genes are a part of that DNA which gives each individual different traits. For instance, if a person has the genes for blue eyes, they will have blue coloured eyes. Similarly, BRCA is a type of gene which stands for Breast Cancer. There are two types of BRCA genes: BRCA1 and BRCA2. These genes produce tumour suppressor proteins which then help in repairing the damaged DNA.

Whenever there is an alteration (mutation) in any of these genes, there is either an absence of the protein formation or formation of faulty proteins. These faulty proteins are incapable of repairing the DNA damage, thus increasing the risk of cancer.

What all cancers have been linked to mutations in BRCA?

Mutations in BRCA1 and BRCA2 can increase the risk of several cancers in both men and women. In women, the mutation of BRCA can lead to the cancer of the breast, ovaries, fallopian tube and peritoneum. In men, BRCA mutations can increase the risk of breast cancer and prostate cancer. Harmful BRCA1 or BRCA2 mutations in both men and women can increase the risk of pancreatic cancer.

Can BRCA mutation run in family?

BRCA mutation can lead to cancer and cancers can run in the family. If you have a family member with a history of ovarian cancer, fallopian tube cancer, breast cancer, male breast cancer, prostate cancer, pancreatic cancer or even melanoma, then it is possible that a BRCA mutation is running in your family.

Are there any tests that can help detect mutations in BRCA1 and BRCA2?

Yes, there are several tests available that can help in determining harmful BRCA1 or BRCA2 gene mutation that has already been recognised in another family member. Multigene panel testing is one such test which uses next-generation sequencing to find out harmful mutations in many genes that are linked with an increased risk of breast and ovarian cancer along with BRCA1 and BRCA2.

For this test, the doctor studies the DNA derived from the blood or saliva samples.

If you have a family history of cancer, you can reach out to a doctor for genetic counselling and theyll be able to guide you further and help you decide if you need genetic testing.

For more information, read our article on Breast Cancer.

Health articles in Firstpost are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.

Updated Date: Jun 16, 2020 22:42:16 IST

Tags : BRCA, BRCA Genes, BRCA Genes In Men, brca1, brca2, Breast Cancer Gene, Breast Cancer Genes, DNA, FDA, Genetic Mutation, Genetic Testing, Health, Mutation, Myupchar, NewsTracker, Olaparib, Reuters, Rucaparib, WHO, World Health Organisation

Read more:
Breast Cancer genes found in both men and women; here's all you need to know about BRCA and genetic testing - Firstpost

It has been another busy week for FDA as the agency made moves to broaden COVID-19 testing including those who are not showing any symptoms of having the virus while also cracking down on fraudulent testsand revoking an antibody test that was previously authorized.

The agency posted template updatesregarding the validation of molecular diagnostic tests for developers that intend their assay to be used for pooling patient samples or for screening asymptomatic individuals not suspected of having COVID-19. The agency also published a FAQswith information regarding tests for screening asymptomatic individuals.

FDA has authorized molecular diagnostic tests for anyone whose healthcare providersuspectsof having the virus that causes COVID-19, whether they are symptomatic, pre-symptomatic, or asymptomatic. It has always been the healthcare provider's discretion to test patients who don't exhibit any of the symptoms if, for example, the individual has been in contact with someone else who has tested positive for the virus. However, FDA says that is not the same as using COVID-19 diagnostic tests as a broad screening tool.

The agency's updated templates for test developers explains FDA's expectations for how a test can be validated for screening of asymptomatic individuals, in an effort to make it easier to get tests authorized for this use. The point is so that organizations can conduct screening as part of a broader strategy to ensure the safety of employees, patients, students, and others.

FDA said that in order to preserve testing resources, many developers are interested in performing their COVID-19 testing using a technique of "pooling" samples, which allows a lab to mix several samples together in a batch or pooled sample and then process the pooled sample with a diagnostic test. For example, four samples may be tested together, using only the resources needed for a single test. If the pooled sample is negative, it can be deduced that all patients were negative. If the pooled sample comes back positive, then each sample needs to be tested individually to find out which was positive.

Because samples are pooled together, ultimately fewer tests are run overall, meaning fewer testing supplies are used, and results can be returned to patients more quickly in most cases, FDA said. The agency warned, however, that because samples are diluted, there is a greater likelihood of false negative results, particularly if not properly validated. The agency said this method works well when there is a low prevalence of cases, meaning more negative results are expected. Testing asymptomatic individuals means testing a greater volume of patients, and a low prevalence may be more likely in an asymptomatic population, particularly if the population is at low risk for contracting COVID-19, FDA said developers may be interested in using pooling techniques in tests for asymptomatic screening.

FDA also slapped three companies with warning letters this week for marketingadulterated and misbranded COVID-19 antibody tests. Generally, antibody tests, also called serological tests, detect antibodies to SARS-CoV-2, which can help identify individuals who have developed an adaptive immune response to the virus, as part of either an active infection or a prior infection. These tests may be important in the fight against this pandemic, the agency noted, as they may provide information on disease prevalence and the frequency of asymptomatic infection. Todays warning letters are the first set of letters the agency has issued for marketing adulterated or misbranded COVID-19 test kits.

Warning letters were issued to:Medakit Ltd.of Sheung Wan, Hong Kong;Antibodiescheck.com and Yama Group; andDr. Jason Korkus, DDS and Sonrisa Family Dental d/b/a My COVID19 Clubof Chicago, Illinois.

Providing regulatory flexibility during this public health emergency never meant we would allow fraud, said Jeff Shuren, MD,director of FDAs Center for Devices and Radiological Health. When tests are marketed inappropriately, with inaccurate or misleading claims such as the ability to perform the test completely at home, or that the test is authorized, cleared, or approved when it is not they put the health of Americans at risk. Such conduct will not be tolerated by the FDA, and we will continue to monitor tests marketed in the U.S., taking appropriate action as warranted.

Violations outlined in the warning letters include: offering test kits for sale in the United States directly to consumers for at-home use without marketing approval, clearance, or authorization from the FDA; misbranding products with labeling that falsely claims products are FDA approved; and labeling that bears the FDA logo.

FDA says consumers and healthcare professionals are encouraged to report suspected fraud to FDA's health fraud program,the Office of Criminal Investigations, or emailFDA-COVID-19-Fraudulent-Products@fda.hhs.gov.

Performance/accuracy concerns prompted FDA to revoke the emergency use authorization ofChembio Diagnostic System's antibody SARS-CoV-2 antibody test, which was among the first COVID-19 antibody tests authorized in the United States. FDA said it previously authorized the test based on information Chembio submitted at the time because the test's known and potential benefits outweighed its known and potential risks.

This week the agency said that as ithas learned more regarding the capability for performance of SARS-CoV-2 antibodytests during the pandemic, and what performance is necessary for users to make well-informed decisions, FDA has developed general performance expectations for these tests, and Chembio's test didn't make the cut.

Data submitted by Chembio as well as an independent evaluation of the Chembio test showed that itgenerates a higher than expected rate of false results and higher than that reflected in the authorized labeling for the device. The agency said that the risk to public health from the false test results makes EUA revocation appropriate.

Since the beginning of the COVID-19 public health emergency, the FDA has balanced the urgent need for access to diagnostic and antibody tests with providing a level of oversight that helps to ensure accurate tests are being deployed, Shuren said. By continuing to monitor authorized tests and emerging scientific evidence, we are able to make changes when appropriate including taking action when a tests benefits no longer outweigh its risks. Through these efforts, we are able to help assure that FDA-authorized tests meet the needs of the American public.

To date, FDA has authorized140testsunder emergency use authorizations, which include 118 moleculartests, 21 antibodytests, and oneantigen test.

The agency also continues to authorize more tests that are designed for at-home sample collection. Most recently, Fulgent Geneticsreceived emergency use authorization for a COVID-19 diagnostic test.Fulgent said it will be offering the testing service through Picture Genetics, the companys consumer-initiated genetic testing platform, beginning next week.

One molecular diagnostic company is cutting through the noise and reaching investors ears with a rapid COVID-19 test. Cue Health said last week it has raised a sizeable $100 million in a series C financing to help support the development and commercialization of its tests, which includes a molecular diagnostic for COVID-19. Speaking of which, Cue Health finished out the week on a high note with FDA authorizing therapid, portable, point-of-care molecular test designed to detectthe RNA of SARS-CoV-2. The test uses a nasal swab sample taken from the lower partof the nose and produces results in 25 minutes, Cue said.

Another significant recent development on the testing front is the addition of next-generation sequencing.FDA gave Illumina the greenlight to bring the first next-generation sequencingCOVID-19 diagnostic test to the U.S. market, which is expected to become a key weapon in the battle against the virus. The test not only expands the United States' testing capabilities, but genetic sequencing information is expected to help scientists monitor if and how the virus mutates, which will be crucial as they continue to learn and fight the virus.

Abbott emerged as an early leader for COVID-19 testing, especially after bringing its ID NOW COVID-19 rapid test to the U.S. market. In May, however, the company went on the defensive after several independent research teams questioned the accuracy of the point-of-care molecular diagnostic test. One study in particular, out of NYU Langone Health,suggested that Abbott's test produced false negative results for almost half of the positive samples in a study of 101 patients. That study was criticized however becausethe patient samples were not collected at the point of care like the test was designed for. Instead, the researchers transported the samples to the hospital's laboratory within one or two hours and then tested using both Abbott's ID NOW machine and Cepheid's Xpert Xpress test. Abbott argued that outcomes of its ID NOW test depend on a number of factors including conformity to the way the test was designed to be run.ID NOW is intended to be used near the patient with a direct swab test method,"

FDA said on May 14 it was investigating concerns about the test, but the agency has not announced any updates or action related to those concerns.

Recently, Abbott published an interim analysis of an ongoingmulti-site clinical studyin urgent care clinics that indicates its ID NOW COVID-19 rapidtestis showing strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments. Abbott said the interim results are demonstrating ID NOW COVID-19test performance is 94.7% in positive agreement (sensitivity) and 98.6% negative agreement (specificity) when compared to two different lab-based PCR reference methods.

Data from this, as well as two otherAbbott-sponsored studies The Everett Clinic in Washington and an ongoingstudyof hospitalized and nursing home patients suggest ID NOW performs best in patientstested earlier post symptom onset, when they are most likely to go for care. In these studies, ID NOW was used as intended with variations in patient populations based on the number of days a patient wastested after first experiencing symptoms, Abbott said.

Read more here:
FDA Looks to Bring COVID-19 Testing to More Americans - Medical Device and Diagnostics Industry

Tempus, a Chicago-based technology company that offers genetic testing and aggregates clinical information, initially focused on cancer patients. But with the coronavirus pandemic spreading across the world, it's joining the fight against Covid-19.

Tempus was founded in 2015 by its CEO, Eric Lefkofsky, who previously co-founded the e-commerce company Groupon in 2008. But while Tempus' mission may seem far removed from that of an online discount marketplace, Lefkofsky had personal reasons for branching out.

"My wife was diagnosed with breast cancer about five years ago, and I was amazed how little data was actually used as a part of her therapy, largely because our system makes it hard for doctors to access data when making real-time clinical decisions," he said. "It became clear to me that I needed to try and tackle this problem, and I founded Tempus soon afterwards."

Tempus, which ranked No. 6 on the 2020 CNBC Disruptor 50 list, has three primary lines of business. It offers genomic tests that physicians can order, its most popular being a test that looks for over 600 genes associated with cancer. (It does not offer any direct-to-consumer genetic testing, like a 23andMe.)

After Groupon co-founder Eric Lefkofsky's wife was diagnosed with breast cancer, he discovered how hard the U.S. health system makes it for doctors to access data in clinical decision-making. That led him to found disease-agnostic AI start-up Tempus, which is now mining patient data for a potential Covid-19 medicine.

Tempus

It also partners with academic medical centers and community health-care systems to organize and aggregate clinical data, primarily data held in electronic health records. The clinical data is de-identified to protect patient privacy, then typically used in research projects to help understand patterns. Tempus claims to have one of the largest molecular and clinical data libraries.

There is crossover between these two businesses, as data from genomic tests that run in its Chicago and Atlanta labs can be de-identified and added to the molecular and clinical data library.

Finally, it curates and sells de-identified data to pharmaceutical companies working on drug discovery.

Tempus is a covered entity under the Health Insurance Portability and Accountability Act (HIPAA), so all of the datais scrubbed of patient name, date of birth, address and any other data point that could identify an individual.

Early on, Lefkofsky felt that the Tempus platform should apply to a broad cross-section of patient data. For this reason the Tempus platform was designed to be what the company calls "disease agnostic," which means it can be applied to patients suffering from many kinds of illnesses, including cancer, depression, diabetes, cardiovascular disease and Covid-19.

In April, Tempus began offering a polymerase chain reaction (PCR) test for Covid-19 from its Chicago and Atlanta laboratories. It currently expects to build its testing capacity to approximately 10,000 tests a day in the coming months. The test, offered through physicians, was rolled out parallel to the start of a research project to gather data on Covid-19 patients and look for patterns that can help physicians treating patients as well as drug-discovery efforts. Procedures may vary from patient to patient, but this is where Lefkofsky thinks the company's AI platform can do the most good.

"We are focused on collecting real-world evidence for patients that are Covid-19 positive to help doctors stratify patients based on risk and help triage patients to the optimal therapeutic path for them, based on their unique phenotypic characteristics," he said.

Dr. Scott Gottlieb, resident fellow at the American Enterprise Institute and special partner at New Enterprise Associates, sits on Tempus' board of directors. He joined after serving as commissioner of the Food and Drug Administration, where he spearheaded efforts to advance the use of artificial intelligence to create individualized patient care.

"I was impressed by the company's ability to rapidly scale its sequencing operations to support major academic institutions and community oncologists across the country and get data to patients and providers," he said. "They were focused not only on the back-end technologies to enable these opportunities, but equally important the front-end interfaces to make this information useful at the point of care."

Artificial intelligence could help us solve a number of serious public health problems and improve outcomes for patients with infectious diseases.

Scott Gottlieb

former FDA commissioner and Tempus board member

It also launched an initiative whose goal is to aggregate data for 50,000 patients who are Covid-19-positive. The hope is that this data will help reveal genetic characteristics that cause specific Covid-19 outcomes, as well as treatment practices for the illness.

Gottlieb added that Tempus is partnering with employers and health-care providers to support Covid-19 testing in states where restrictions are being relaxed, and employees are going back to work, so they'll know what to watch out for.

"We're going to have to be more aggressive in detecting and identifying respiratory viruses," he said. "To these ends, Tempus is also working on a next-generation sequencing panel for respiratory pathogens, including Covid-19, to diagnose patients and create a library for infectious disease research that could reduce the impact of future epidemics."

While Tempus' use of health data as a way to accelerate research shows promise, there are limitations.

Dr. Jose Morey, Chief Medical Innovation Officer for Liberty BioSecurity and advisor for MIT Solve and NASA iTech, said that one problem in relying on AI in the case of a new virus is that there isn't enough data at the moment.

"You have to have large data sets to be able to train, test, and validate," he said. "When you have something new and novel like this, they just don't exist. ... It will come eventually, but not yet."

More from Disruptor 50:Meet the 2020 CNBC Disruptor 50 companiesThe technology that will dominate daily life on the other side of coronavirusOpportunity Missed: Why there are no Black CEOs on this year's list

He added that the technology is also only as good as the data, and currently, there are systemic flaws in the way medical data is gathered and recorded. For example, he said that data in medical centers could be "dirty."

"This means that the data is not structured to be plugged into the math that is AI,'" he said. He added that health-care data is also frequently "siloed," or separated into unconnected compartments. For AI to do its job, it requires large amounts of interconnected data, which Morey said doesn't exist in the U.S. health-care system.

"Health-care entities, such as device manufacturers, electronic medical record vendors, and hospitals, are not incentivized to share data amongst each other," he said. "This is why there are so many AI companies doing incremental algorithm and application development."

In April, Tempus began offering a polymerase chain reaction (PCR) test from its Chicago and Atlanta laboratories. It expects to build its testing capacity to 10,000 tests a day in the coming months and hopes to aggregate data for 50,000 patients who are Covid-19-positive.

Tempus

While this is a challenging moment for the U.S. health-care system, Tempus has been recognized by the medical community and investors as a company whose platform shows great promise.

The company has raised $620 million from investors such as Baillie Gifford, Franklin Resourcesand T. Rowe Price,and is valued at $5 billion. It has also entered into a partnership with CVS Health, which allows oncologists in the CVS Health/Aetna network to use the results of its genomic sequencing tests.

Covid-19 research, like cancer research, has yet to yield a cure. However, Gottlieb said that he sees AI tools as indispensable for cancer patients, infectious disease patients and others in the future.

"As we collect more data and apply AI tools to large datasets, we can direct care to patients at greatest risk," he said. "Artificial intelligence could help us solve a number of serious public health problems and improve outcomes for patients with infectious diseases."

Correction: Tempus has raised $620 million from investors at a valuation of $5 billion. An earlier version of this article misstated the fundraising amount.

Disclosure: Scott Gottlieb is a CNBC contributor.

Original post:
Tempus: Health start-up backed by Groupon co-founder joins the fight against Covid-19 - CNBC

Federal and state law already prevents health insurers from using DNA data to influence their coverage. But Florida lawmakers want to expand that privacy to life, disability and long-term care insurance.

With that bill (HB 1189) now on his desk, Gov. Ron DeSantiswill offer the final say on whether the Sunshine State will become the first state to bar those insurance companies from using genetic tests like 23andMe for coverage purposes. And because incoming House SpeakerChris Sprowls spearheaded the effort, the Governor isnt likely to take out his veto pen.

Sprowls said he discovered the issue in December 2017 when he was applying for life insurance. While he was on hold on the telephone waiting for assistance, he said he was struck by commercials from companies such as 23andMe and AncestryDNA encouraging people to buy genetic tests.

Insurers have noted that information gleaned from genetic testing, such as a persons medical predispositions, could be used to lower insurance premiums across the board. But while it hasnt happened yet, that would punish genetic losers who would see a premium hike, lawmakers said.

The Senate approved the bill 35-3 with Democratic Sen. Kevin Raderand Republican Sens.Jeff BrandesandJoe Grutersdissenting. The amended proposal, which outlined that insurers could use genetic information if it came from a medical diagnosis, passed the House unanimously.

Dr.Robert Gleeson, a medical consultant for the American Council of Life Insurers, hasopposed the bill in past years.

Sen.Kelli Stargel led the Senate effort.

While countless Floridians have used DNA testing kits to learn more about their background or identify potential health risks, they didnt sign up in order for insurers to access this personal information and then base their policies on it, Stargel said in a prepared statement at the bills passage. We are elected to protect Floridians, and this good public policy protects them from insurers invading their private personal DNA data and using it against them.

DeSantis has until June 30 to veto the bill before it goes into effect July 1.

More here:
Gov. DeSantis to decide whether to expand DNA protections from insurers - Florida Politics

Using the mostcomprehensive genomic test availablerapid Whole Genome Sequencing (rWGS)the program called Project Baby Bear analyzed the genetic code of 178 infants to provide doctors and families with vital diagnostic information that empowered them tomake life-altering medical decisions resulting in shorter hospital stays, fewer invasive procedures and targeted personalized care.

"Among high-risk infants with rare, genetically determined diseases, time-to-treatment is crucial," said Stephen Kingsmore, MD, DSc, President and CEO of Rady Children's Institute for Genome Medicine (RCIGM). "Project Baby Bear significantly shortened the time needed to accurately diagnose and optimally treat these critically ill children."

Project Baby Bear helpeddoctors identifythe exact cause of rare, genetic diseasesin an average of three days, instead of the four to six weeks standard genetic testing offers. This allowed physicians to deliver timely treatment tailored to the baby's specific condition.

Through the program, Rady Children's Institute for Genomic Medicine provided rapid Whole Genome Sequencing for 178 babies eligible for Medi-Cal, resulting in a diagnosis for 43% that explained the reason for the infant's admission to the hospital; 31% had changes in their medical care as a result of rWGS.

In addition, substantial reductions in healthcare spending$2.5 millionaccrued largely because rWGS permitted doctors to discharge babies sooner (513 fewer hospital days) and reduce the number of procedures that may have been performed in the absence of a precise diagnosis. Avoided procedures included 11 major surgeries and 16 fewer diagnostic tests including open muscle, liver and other biopsies that are performed under general anesthesia.

"The economic data from Project Baby Bear showed that in addition to life-changing health benefits there are cost savings in getting a quick diagnosis from a single comprehensive test," said David Dimmock, MD, RCIGM Senior Medical Director. "Doctors were able to avoid additional testing, ineffective treatments and lengthy hospitalizations that would have resulted in greater pain and medical spending."

Project Baby Bear was funded by the State of California as a $2-million Medi-Cal pilot aimed at examining the benefits of using rWGS to help improve outcomes for infants hospitalized in intensive care with undiagnosed illness and whether the use of this technology would be cost effective.

Patient blood samples were sent to RCIGM for sequencing and interpretation from the California Children's Services accredited regional neonatal and pediatric intensive care units at the following participating hospitals:

The program was championed by Assemblymember Todd Gloria (San Diego) in partnership with the California Legislative Rare Disease Caucus led by Assemblymembers Brian Maienschein (San Diego) and Rob Bonta (Oakland). Strong support also came fromState Senate President Pro Tem Toni Atkins (San Diego); and Assemblymembers Joaquin Arambula, MD (Fresno); and Marie Waldron (San Diego).

Until the initiation of Project Baby Bear, Whole Genome Sequencing had not been covered by private insurance nor public health programs and was available only through clinical trials paid for by research grants or philanthropic donations.

"Project Baby Bear has shown that California is once again leading the way in improving the lives of children and families faced with unexplained rare diseases," said Patrick Frias, President and CEO of Rady Children's Hospital-San Diego. "Based on the results of this demonstration program, California is now in a position to be the first state to make this life-changing diagnostic solution available to every child who needs it."

Encouraged by the early success of Project Baby Bear, the State of Florida and State of Michigan have since initiated their own publicly-funded rWGS demonstration projects. In addition, San Diego Congressman Scott Peters introduced "Ending the Diagnostic Odyssey Act of 2019" that would provide rapid Whole Genome Sequencing to diagnose children with critical unexplained conditions. That bill, HR 4144, as well as is a counterpart bill in the U.S. Senate, are now pending.

Project Baby Bear Final State Report https://radygenomics.org/wp-content/uploads/2020/06/PBB-Final-Report_06.16.20.pdf

About Rady Children's Institute for Genomic Medicine: The Institute is leading the way in advancing precision healthcare for infants and children through genomic and systems medicine research. Discoveries at the Institute are enabling rapid diagnosis and targeted treatment of critically ill newborns and pediatric patients at Rady Children's Hospital-San Diego and collaborating hospitals. The vision is to expand delivery of this life-saving technology to enable the practice of precision pediatric medicine at children's hospitals across California, the nation and the world. RCIGM is a subsidiary of Rady Children's Hospital and Health Center. Learn more at http://www.RadyGenomics.org. Follow us on Twitterand LinkedIn.

About Rady Children's Hospital-San Diego: Rady Children's Hospital-San Diegois a 505-bed pediatric care facility providing the largest source of comprehensive pediatric medical services in San Diego, southern Riverside and Imperial counties. Rady Children's is the only hospital in the San Diego area dedicated exclusively to pediatric healthcare and is the region's only designated pediatric trauma center. In June 2020, U.S. News & World Report ranked Rady Children's among the best children's hospitals in the nation in all ten pediatric specialties the magazine surveyed. Rady Children's is a nonprofit organization that relies on donations to support its mission. For more information, visit http://www.rchsd.org and find us onFacebook,TwitterandVimeo.

Media Contact: Grace Sevilla Office: 858-966-1710 Cell: 619-855-5135 [emailprotected]

SOURCE The Rady Childrens Institute for Genomic Medicine (RCIGM)

View original post here:
Rady Children's Shows Genomic Sequencing for Infants in Intensive Care Yields Life-Changing Benefits and Medical Cost Savings - PRNewswire

Global Breast Cancer Predictive Genetic Testing Market OverviewGlobal Breast Cancer Predictive Genetic Testing Market presents insights on the current and future industry trends, enabling the readers to identify the products and services, hence driving the revenue growth and profitability. The research report provides a detailed analysis of all the major factors impacting the market on a global and regional scale, including drivers, constraints, threats, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

The novel COVID-19 pandemic has put the world on a standstill, affecting major operations, leading to an industrial catastrophe. This report presented by Garner Insights contains a thorough analysis of the pre and post pandemic market scenarios. This report covers all the recent development and changes recorded during the COVID-19 outbreak.

Understand the influence of COVID-19 on the Breast Cancer Predictive Genetic Testing Market Size with our analysts monitoring the situation across the globe.

Access PDF Sample Copy of the Report, With 30 mins free consultation! Click here@https://garnerinsights.com/Global-Breast-Cancer-Predictive-Genetic-Testing-Market-Size-Status-and-Forecast-2020-2026#request-sample

This Breast Cancer Predictive Genetic Testing market report aims to provide all the participants and the vendors will all the details about growth factors, shortcomings, threats, and the profitable opportunities that the market will present in the near future. The report also features the revenue share, industry size, production volume, and consumption in order to gain insights about the politics to contest for gaining control of a large portion of the market share.

Top Key Players in the Breast Cancer Predictive Genetic Testing Market: Amgen,Celgene,MagForce AG,Nanotherapeutics,Spectrum Pharmaceuticals,Ablynx,AMAG,CytImmune,Delpor,Nanospectra,Merrimack,Tarveda,.

Competitive landscapeThe Breast Cancer Predictive Genetic Testing Industry is severely competitive and fragmented due to the existence of various established players taking part in different marketing strategies to increase their market share. The vendors operating in the market are profiled based on price, quality, brand, product differentiation, and product portfolio. The vendors are turning their focus increasingly on product customization through customer interaction.Breast Cancer Predictive Genetic Testing Market segment by Regions/Countries: United States, Europe, China, Japan, Southeast Asia, India, Central & South America.

To get this report at a profitable rate.: https://garnerinsights.com/Global-Breast-Cancer-Predictive-Genetic-Testing-Market-Size-Status-and-Forecast-2020-2026#discount

Major Types of Breast Cancer Predictive Genetic Testing covered are:High Penetrant Genes,Intermediate Penetrant Genes,Low Penetrant Genes,

Major end-user applications for Breast Cancer Predictive Genetic Testing market:Hospitals,Clinics,Other,

Points Covered in The Report:

Reasons for Buying Global Breast Cancer Predictive Genetic Testing Market Report:

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.garnerinsights.com/Global-Breast-Cancer-Predictive-Genetic-Testing-Market-Size-Status-and-Forecast-2020-2026Thanks for reading this article; you can also get individual chapter wise section or region wise report version like Asia, United States, Europe.

Contact Us:Kevin ThomasContact No: +1 513 549 5911 (US)+44 203 318 2846 (UK)sales@garnerinsights.com

Read more:
Impact of Covid-19 on Breast Cancer Predictive Genetic Testing Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Amgen,...

London, June 16, 2020 (GLOBE NEWSWIRE) -- The non-invasive prenatal testing market is expected to grow at a CAGR of 17.1% from 2019 to 2027 to reach $13.14 billion by 2027.

With the emergence of innovative diagnostic and screening techniques, several methods of genetic testing are gaining popularity. These include carrier testing, preimplantation genetic diagnosis / screening (PGD / PGS), non-invasive prenatal testing (NIPT), paternity testing, and newborn screening. Technological advancements in the healthcare industry such as wearable healthcare devices, sequencing technologies, regenerative medicine, and genomic technologies, supported by breakthroughs in the field of genome sequencing and molecular research have opened new and promising pathways to combat genetic diseases and reduce the overall global economic burden.

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5068

Among the innumerable advancements witnessed by the industry, non-invasive prenatal testing stands as one of the most distinctive technologies in curbing the concerns related to genetic diseases. NIPT a novel genetic screening method based on the analysis of cell-free fetal deoxyribose nucleic acid (cff-DNA) in the maternal plasma is considered as a valuable test for pregnant women, which provides early diagnosis of genetic disorders in fetus.

Further, advancements in genome sequencing technologies have reduced the turnaround time and lowered complexities associated with diagnosis. NGS technology provides several avenues to develop non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. This is driving several companies to invest in research and development of NGS-based NIPT products and develop innovative solutions for the market. For instance, in January 2019, Yourgene Health plc (U.K.) launched the Sage 32 plex test which uses Thermo Fishers Ion Torrent sequencing technology to detect placental cff-DNA in a maternal blood sample. Similarly, in September 2018, Yourgene Health formerly known as Premaitha Health plc. (U.K.) partnered with Illumina Inc. (U.S.) to use the Illuminas sequencing technology for the NIPT test developed by Premaitha.

The growth in the overall NIPT market is majorly driven by factors like shifting trend towards childbirth at an advanced maternal age, increasing prevalence of chromosomal abnormalities, availability of reimbursement for NIPT, and development of advanced technologies for non-invasive parenteral testing. However, the high cost of the non-invasive prenatal screening techniques hinders the growth of this market.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5068

The global non-invasive prenatal testing market studied in this report is segmented on the basis of product & solutions type (kits / consumables, systems, software), method (ultrasound screening & cell free DNA screening), application (trisomies, microdeletions, & sex chromosomal abnormalities), end user (diagnostic laboratories, hospitals, and academic & research institutes), and geography

On the basis of product and solution type, the kits / consumables segment commanded the largest share of the overall non-invasive prenatal testing market in 2019. The major share of this segment is attributed to the increasing incidence of chromosomal abnormalities, rise in the number of tests and products for NIPT, and improvement in regulatory approvals for NIPT assays.

On the basis of method, cell free DNA screening commanded the largest share of the overall non-invasive prenatal testing market in 2019. Technological advancements, increasing initiatives by companies to develop new NIPT products, and growing awareness for prenatal testing among pregnant women are the major factors driving the growth of the cell free DNA screening method for non-invasive prenatal testing.

On the basis of application, trisomy detection commanded the largest share of the overall non-invasive prenatal testing market in 2019. Rising incidences of trisomy due to increasing maternal age, higher accuracy of NIPT methods in trisomy detection, and lower cost of NIPT to detect trisomy as compared to other invasive methods are the major factors driving the growth of the NIPT products and solutions market for trisomy detection application.

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/non-invasive-prenatal-testing-market-5068/

On the basis of end user, diagnostic laboratories commanded the largest share of the overall non-invasive prenatal testing market in 2019. Availability of the well-equipped facility and trained/skilled technicians and significant investments by government agencies to improve healthcare infrastructure are some of the key factors attributed to large share of diagnostic laboratories in the non-invasive prenatal testing market.

Geographically, the global non-invasive prenatal testing market is segmented into five major regions, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa with a further analysis of major countries in each region. North America commanded the largest share of the global non-invasive prenatal testing market in 2019, followed by Europe and Asia-Pacific region. The major share of the North American region is mainly attributed to the high diagnostic and treatment rate of trisomy disorders in the region, high awareness for prenatal testing, and presence of laboratories offering NIPT services in the region.

Some of the key players operating in the global non-invasive prenatal testing market are Illumina, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.S.), PerkinElmer Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Eurofins LifeCodexx (Germany), Natera, Inc. (U.S.), Igenomix S.L (Spain), Laboratory Corporation of America Holdings (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), and Yourgene Health plc (U.K.).

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5068

Amidst this crisis, Meticulous Researchis continuously assessing the impact of COVID-19 pandemic on various sub-markets and enables global organizations to strategize for the post-COVID-19 world and sustain their growth. Let us know if you would like to assess the impact of COVID-19 on any industry here-https://www.meticulousresearch.com/custom-research.php

Related Reports:

Next Generation Sequencing Services Market by Service Type (Targeted Sequencing, Exome, RNA-Seq, ChIP Sequencing), Technology (Sequencing by Synthesis, Nanopore, SMRT), Application (Clinical Diagnosis, Biomarker Discovery), and End User - Global Forecast to 2025

https://www.meticulousresearch.com/product/next-generation-sequencing-ngs-services-market-5041/

Next Generation Sequencing Market by Type (Consumables, NGS Platform, Software), Sequencing Type (Whole Genome, Targeted), Technology (Sequencing by Synthesis, Sequencing by Ligation), Application (Clinical, Research), End User - Global Forecasts to 2025

https://www.meticulousresearch.com/product/next-generationg-sequencing-market-5040/

Clinical Genomics Market By Test Type (Diagnostic, Genetic, Newborn Screening, Prenatal, Carrier Screening), Software, Method (Molecular, Chromosomal, Biochemical Tests), End User (Hospitals and Clinics) - Global Forecast to 2023

https://www.meticulousresearch.com/product/clinical-genomics-market-forecast-2023/

Research Antibodies and Reagents Market by Product (Reagent [Sample Preparation (Media, Probe, Buffer), Antibody Production Reagent], Antibody [Type, Source, Research Area]), Technology (Western Blot, ELISA), Application, End User - Global Forecast to 2025

https://www.meticulousresearch.com/product/research-antibodies-reagents-market-5055/

Next Generation Sequencing Informatics Market (NGS Informatics Market) Size by Product and Services, by Function, by Application, by End - Global Forecast to 2022

https://www.meticulousresearch.com/product/ngs-informatics-market-forecast/

About Meticulous Research

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.

With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

See the rest here:
Non-Invasive Prenatal Testing (NIPT) Market Worth $13.14 Billion by 2027, Growing at a CAGR of 17.1% from 2019- Global Opportunity Analysis and...

The global market for high-resolution melting analysis is gaining momentum on account of the advancements in molecular biology. High-resolution melting analysis involves the microscopic study of double-stranded DNA samples to successively detect polymorphisms, epigenetics, and mutations. The study involves the amplification of the region where the mutational analysis needs to be carried out and generation of multiple copies of that region in the sample tube. The applications of high-resolution melting analysis in molecular biology are expansive, which is expected to play to the advantage of the market. TMR Research throws light on several market forces that are expected to contribute to the growth of the market over the coming. Moreover, a multifaceted approach to understand the knit and grit of the market was followed during research and analysis.

Request Sample of High-resolution Melting Analysis Market Report for more Industry Insights @CLICK HERE NOW

One of the most important applications of point high-resolution melting (HRM) analysis is the detection of point mutation. The conventional method of SNP typing is expensive and time-consuming which shifts the focus on HRM analysis. Testing of zygotes has also emerged as an important application of HRM analysis, which is propelling demand within the global market. Apart from the above-mentioned applications, intercalating dyes used for the transition of double-standard DNAs to single-stranded ones are another key area that is projected to contribute to the growth of the market.

Genetic testing centers have been specifically very successful in North America which has given an impetus to the market. On the other hand, prominence of academic Institutes and research centers in Europe has also contributed to the growth of the regional market.

Global High-resolution Melting Analysis Market: Overview

High resolution melting analysis is a powerful and strong methodology in molecular biology for the purpose of detecting epigenetic differences, polymorphisms, and mutations in double-stranded DNA samples. It was first discovered and developed by the Idaho Technology and University of Utah. High resolution melting analysis has several advantages over genotyping technologies such as cost effectiveness, it is powerful and fast as compared to genotyping technologies, and it is comparatively simple. Based on products and services, the global high-resolution melting analysis market can be segmented into software and services, consumables and reagents, and instruments. In terms of application, it can be segmented into epigenetics, pathogen identification, species identification, mutation scanning, and SNP genotyping.

The global market for high-resolution melting analysis is likely to have a fruitful future owing to ongoing research and developments in this field sponsored by several leading companies operating in this particular field. For instance, FDA in the U.S. approves many treatments which are made for addressing a specific genomic profile or genetic makeup of the tumor of the patient.

Global High-resolution Melting Analysis Market: Drivers and Restraints

The prime factors that are boosting the growth of the market comprise the growing prevalence of cardiovascular diseases, COPD, chronic diseases such as cancer, and other different infectious diseases. The prime benefits associated with high-resolution melting analysis are optimization of therapies, patient compliance, drug safety, cost savings on several treatments, and disease diagnosis. In return, these are also expected to propel the demand for DNA testing services. Moreover, rising awareness pertaining to the applications of high resolution melting analysis technologies for HLA typing, mutation discovery, and DNA mapping are additional aspects that are anticipated to propel the growth of the high-resolution melting analysis market during the forecast period. High resolution melting analysis is a technology employed for assessing melting curve plots of amplified gene. This particular technology is basically used for gene mutation scanning, microbial species identification, methylation profiling, and other different diagnostics based on PCR. Thus, mutation scanning and other applications are likely to gain prominence over time owing to rising prevalence of advancements in technology of molecular biology, genetic disorders, and growing awareness pertaining to SNP typing.

Global High-resolution Melting Analysis Market: Market Potential

Growing government budget provision for research and development in the field of pharmaceuticals, biotechnology, and applied life sciences is a crucial factor heightening the demand for numerous diagnostic techniques and tools. For instance, in 2015, the Obama led administration announced the introduction of the Precision Medicine Initiative with a huge investment of US$216 mn in the Presidents budget of 2016. This initiative is further expected to have positive impact on the growth of the high resolution melting analysis market.

Global High-resolution Melting Analysis Market: Regional Overview

Region-wise, the market can be segmented into North America, Asia Pacific, Europe, and the Rest of the World. North America is expected to perform extremely owing to factors such as robust adoption of advanced technology in healthcare, numerous genetic testing centers, strong biotech and pharmaceutical industry, prevalence many academic universities, and high prevalence of diseases. Asia Pacific has also been identified as one of the potential regions where the market can grow steadily owing to dynamics such as rising prevalence of chronic diseases such as HIV, COPD, and cancer, growing cases of genetic disorders, and rising private and public expenditure on genetic testing and molecular diagnostic.

Get TOC of High-resolution Melting Analysis Market Report for more Industry Insights @CLICK HERE NOW

Global High-resolution Melting Analysis Market: Competitive Landscape

The top drawer companies operating in the market areThermo Fisher Scientific, Kapa Biosystems, Idaho Technology Corporation, and Roche Molecular Systems.

See the original post here:
High-resolution Melting Analysis Market Current Outlook Of Industry & Forecast 2017-2025 - Owned

Dallas, Texas, June 15, 2020 (GLOBE NEWSWIRE) -- The Global Preimplantation Genetic Testing Market Size 2018, By Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism) Region and Forecast 2019 to 2025 study provides an elaborative view of historic, present and forecasted market estimates.

Request a pdf sample @https://www.adroitmarketresearch.com/contacts/request-sample/1483

Adroit Market Research report on global preimplantation genetic testing market gives a holistic view of the market from 2015 to 2025, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2015 to 2017, with the base year of estimation as 2018 and forecast from 2019 to 2025. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global preimplantation genetic testing market have been studied in detail.

The global preimplantation genetic testing market is projected to reach USD 1,147.9 million by 2025, growing at a CAGR of 11.8%. Increasing rate of infertility worldwide, growing number of fertility clinics across the globe, public-private investments in the field of preimplantation genetic testing, high risk of chromosomal abnormalities in the fetus with increasing maternal age and technological advancements in the field of genetic analysis are the factors driving the growth of the preimplantation genetic testing market.

Browse the complete report with Table of Contents and List of Figures @https://www.adroitmarketresearch.com/industry-reports/preimplantation-genetic-testing-market

Preimplantation genetic testing is a process in which embryos developed outside the womb are tested for particular genetic characteristics, usually genetic abnormalities that cause serious disease, before being transferred to a womans uterus. Preimplantation genetic testing owes its existence to advances in the world of reproductive medicine and genetics that occurred in the late 20th century. Though initially developed as a means to detect serious genetic conditions, preimplantation genetic testing can be used for other purposes. In fact, virtually any of the hundreds of genetic tests now commercially available, and the many more in development, could be used to test embryos. However, socio-ethical concerns regarding preimplantation genetic testing is a major challenge surrounding the market.

The global preimplantation genetic testing market is categorized based on test type and technology. Based on technology, the market is segmented into next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, comparative genomic hybridization and single-nucleotide polymorphism. Next-generation sequencing held the largest market share in 2018. The benefits of NGS include:

It allows simultaneous analysis of 24 chromosomes with higher resolution It offers the possibility to analyze chromosomal aneuploidy and monogenic diseases (caused by mutations in a single gene) separately or simultaneously in a single assay Reduced analysis time, avoiding the need to freeze the embryos while awaiting results It allows the simultaneous analysis of several embryos on a single test which directly affects the cost of analysis.

Direct purchase the singe user copy @https://www.adroitmarketresearch.com/researchreport/purchase/1483

In 2018, North America was the largest market for preimplantation genetic testing owing to rising number of IVF procedures and substantial adoption of genomic techniques. Moreover, Asia Pacific is projected to grow at a highest pace during the forecast period. Key players of the preimplantation genetic testing market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology among others.

Major points from Table of Contents:1. Introduction2. Research Methodology3. Market Outlook4. Preimplantation genetic testing Market by Test Type, 2015-2025 (USD Million)5. Preimplantation genetic testing Market by Technology, 2015-2025 (USD Million)6. Preimplantation genetic testing Market by Region 2015-2025 (USD Million)7. Competitive Landscape8. Company Profiles9. Appendix

Access research repository of Upcoming Reports @ https://adroitmarketresearch.com/upcoming.html

About Us:Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Link:
Preimplantation Genetic Testing Market to grow at 11.8% CAGR to hit US $1,147.9 million by 2025 Insights on Trends, Growth Drivers, Key Stakeholders,...

Latest updates on Direct-To-Consumer (DTC) Genetic Testing market, a comprehensive study enumerating the latest price trends and pivotal drivers rendering a positive impact on the industry landscape. Further, the report is inclusive of the competitive terrain of this vertical in addition to the market share analysis and the contribution of the prominent contenders toward the overall industry.

Consumers send the company a DNA sample like urine or saliva and collect their results directly from a written report or from a secure website. DTC genetic testing further provides access to people for their genetic information without the need for involving any health insurance company or a healthcare provider in the process.

Direct-to-consumer genetic testing market is anticipated to record a substantial growth rate over the coming years due to ongoing technological advancements. Direct-to-consumer genetic testing differs from typical genetic testing. These genetic tests are marketed directly to consumers through the medium of print advertisements, internet, or television, and can be bought in stores or online.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/3974

DTC genetic testing, home DNA testing, direct-access genetic testing, and at-home genetic testing are other names for direct-to-consumer genetic testing.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/3974

Not all DTC tests are genetic tests, some are helpful in measuring other things like levels of toxins in urine, or levels of proteins in the human body and types of bacteria flora usually referred as microbiome.

The direct-to-consumer genetic testing market is bifurcated in terms of test type, technology, distribution channel, and regional landscape.

Numerous companies are now offering DTC genetic tests for several purposes. The most common tests use genetic deviations to make estimates about health, give information regarding common traits, and also offer clues about an individual's ancestry. There is a rise in a number of companies providing DTC testing together with the range of health conditions and traits covered by these tests.

With respect to test type, the market is classified into predictive testing, nutrigenomic testing, ancestry, and relationship testing, carrier testing, and others. Among these, carrier testing is set to observe around 14% CAGR between 2020 to 2028, owing to the growing cases of rare genetic diseases that is affecting millions of people globally.

Based on technology, the market is segmented into whole genome sequencing (WGS), single nucleotide polymorphism (SNP) chips, and targeted analysis. Among these, SNP chips held around 50% market share, owing to the technology's efficacy and cost-effectiveness.

Based on distribution channel, the market is categorized into online platforms and over the counter. Among these, the over the counter distribution channel is likely to observe a market value of more than $730 million by 2028, owing to the ease for the customers in purchasing a test kit, especially those living in rural areas of developing nations.

From a regional frame of reference, the Latin America direct-to-consumer genetic testing market is anticipated to record a market value of around $377 million by 2028, attributable to the rising awareness about cost-effective genetic testing options among general population.

Major Highlights from Table of contents are listed below for quick lookup into Direct-To-Consumer (DTC) Genetic Testing Market report

Chapter 1. Competitive Landscape

Chapter 2. Company Profiles

Chapter 3. Methodology & Scope

Chapter 4. Executive Summary

Chapter 5. Direct-To-Consumer (DTC) Genetic Testing industryInsights

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/3974

See the original post:
Direct-To-Consumer (DTC) Genetic Testing - Market Share Analysis and Research Report by 2025 - CueReport

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hereditary Testing market.

Trusted Business Insights presents an updated and Latest Study on Hereditary Testing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hereditary Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Hereditary Testing Market

The global hereditary testing market size was valued at USD 5.8 billion in 2019 and is projected to register at a CAGR of 6.3% during the forecast period. The expanding reproductive genetic health space is one of the key market drivers. Key players, such as Natera, have reported a continuous increase in test volumes in womens health genetic testing for inherited conditions. This reflects the growing acceptance of hereditary tests among the population, thereby accelerating the revenue growth.Furthermore, a consistent rise in demand for newborn screening has led to an increase in sales of DNA testing kits. For instance, in November 2019, the Division of Consolidated Laboratory Services (DCLS) of the Virginia Department of General Services screened 7,868 newborns for nearly 31 hereditary and metabolic disorders. Increasing penetration of newborn screening across the globe is further aiding in the revenue growth.

Reforms in genetic testing guidelines have led to inclusion of multigene panel testing for hereditary cancer into clinical practice. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers offers information on some of the cancer risk factors and management recommendations for single and multiple gene panels.Gradual developments in the distribution model is likely to benefit the genetic testing market. Technology providers are playing a crucial role in the market growth by improving their distribution service and increasing the efficiency of technology. Companies are using a cloud-based distribution model to make bioinformatics technology available for use by other laboratories. As of March, 2019, around 14 licensees were using Constellation software commercially for the marketing of Non-invasive Prenatal Testing (NIPT) products.Although these hereditary tests have huge advantages over conventional tests, several industry experts cited the cost and security concerns faced by consumers pertaining to the test. Moreover, lack of effective regulation of the tests is another key area that demands focused efforts. Despite these challenges, the genetic testing market is constantly expanding owing to the advantages of these innovative tests along with improved healthcare outcomes.DiseaseType Insights of Hereditary Testing Market

Product and service offerings with regard to various hereditary cancer testing continue to expand. Entry of major players, such as Quest, in this segment in the recent past, has significantly driven the hereditary testing market. Considering breast cancer genetic testing as a lucrative source of revenue, companies are focusing on business strategies to enhance their presence in this segment.One of the strategies is offering hereditary tests at a price lower than that offered by competitors. For instance, Color Genomics began selling its product for USD 259, whereas similar products offered by Myriad cost around USD 4,000. The increasing affordability of the tests is one of the key drivers of this segment. Furthermore, BRCA1 carriers have an 80% risk of developing breast cancer, which has also accelerated the developments in hereditary cancer testing market.

On the other hand, lung cancer is one of the major cancer forms that has a relatively few number of products. This is because most cases of lung cancer are not related to inherited genetic mutations. Similarly, for cervical cancer, most of the cases are caused by Human Papilloma Virus (HPV) and not genetic mutations. Lack of effective evidence over heritability of cervical cancer are driving the research activities in this market.Prenatal testing, irrespective of the associated risks, is increasingly gaining popularity. The cell-free DNA (cfDNA)-based NIPT testing is considered medically necessary by Anthem Blue Cross and Blue Shield of California. Previously, these players promoted cfDNA-based NIPT testing for trisomys 21, 18, and 13 only in high-risk pregnancies, as determined by maternal age and other factors.

Regional Insights of Hereditary Testing Market

Variations in regulatory frameworks pertaining to genetic tests across the world have significantly impacted the approval and commercialization of tests in the global market. Currently, a wide variety of genetic tests are being provided by several key companies in U.S. as well as several countries in Europe, Asia Pacific, and other regions.Europe accounted for the largest share in terms of revenue in 2019 and is likely to continue its dominance during the forecast period. This can be attributed to presence of key players providing genetic tests, high adoption of advanced treatments, and recommendations provided by government agencies to ensure the quality of hereditary testing services.In September 2019, Blueprint Genetics, a Finnish company, partnered with ARCHIMEDlife, a rare disease diagnostics company, to provide biochemical testing for rare diseases in North America. Through this partnership, both firms planned to diversify their range of genetic disease testing services to serve the customers better. Such initiatives are expected to strengthen the genetic testing scenario for hereditary disorders in North America, thereby accelerating regional revenue generation.

Market Share Insights of Hereditary Testing Market

Understanding the role of genetic mutation in disease occurrence has significantly accelerated the R&D in this market. Various retrospective studies are being carried out to understand the role of inherited mutations in disease pathology, which has led to key diagnostic developers, such as Quest Diagnostics, enter the market. Continuous authorizations and approvals of genetic tests by the government is expected to propel the organic revenue growth of operating companies.Some of the key players engaged in offering services and products in this market are Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.; Twist Bioscience; Sophia Genetics; Fulgent Genetic, Inc.; Medgenome; and CENTOGENE N.V.Furthermore, the expanding product portfolio is indicative of growing competition in the market. Each company is making focused efforts to offer products with competitive advantage. For example, cross-selling efforts by Natera helped the company witness lucrative revenue generation over the past years. The company promotes collective use of Horizon and Panorama products for women who have not undergone carrier screening tests in their first trimester.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Hereditary Testing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global hereditary testing market report on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2019 2030)

Hereditary Cancer Testing

Lung Cancer

Breast Cancer

Colorectal Cancer

Cervical Cancer

Ovarian Cancer

Prostate Cancer

Stomach/Gastric Cancer

Melanoma

Sarcoma

Uterine Cancer

Pancreatic Cancer

Others

Hereditary Non-cancer Testing

Genetic Tests

Cardiac Diseases

Rare Diseases

Other Diseases

Newborn Genetic Screening

Preimplantation Genetic Diagnosis & Screening

Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests

Quick Read Table of Contents of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the rest here:
Hereditary Testing Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 - 3rd Watch News

Preimplantation Genetic Testing Market Overview

The Preimplantation Genetic Testing market report presents a detailed evaluation of the market. The report focuses on providing a holistic overview with a forecast period of the report extending from 2018 to 2026. The Preimplantation Genetic Testing market report includes analysis in terms of both quantitative and qualitative data, taking into factors such as Product pricing, Product penetration, Country GDP, movement of parent market & child markets, End application industries, etc. The report is defined by bifurcating various parts of the market into segments which provide an understanding of different aspects of the market.

The overall report is divided into the following primary sections: segments, market outlook, competitive landscape and company profiles. The segments cover various aspects of the market, from the trends that are affecting the market to major market players, in turn providing a well-rounded assessment of the market. In terms of the market outlook section, the report provides a study of the major market dynamics that are playing a substantial role in the market. The market outlook section is further categorized into sections; drivers, restraints, opportunities and challenges. The drivers and restraints cover the internal factors of the market whereas opportunities and challenges are the external factors that are affecting the market. The market outlook section also comprises Porters Five Forces analysis (which explains buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Preimplantation Genetic Testing) in addition to the market dynamics.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24037&utm_source=JLN&utm_medium=005

Leading Preimplantation Genetic Testing manufacturers/companies operating at both regional and global levels:

Preimplantation Genetic Testing Market Scope Of The Report

This report offers past, present as well as future analysis and estimates for the Preimplantation Genetic Testing market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. The research methodology that is adopted involves multiple channels of research, chiefly primary interviews, secondary research and subject matter expert advice. The market estimates are calculated on the basis of the degree of impact of the current market dynamics along with various economic, social and political factors on the Preimplantation Genetic Testing market. Both positive as well as negative changes to the market are taken into consideration for the market estimates.

Preimplantation Genetic Testing Market Competitive Landscape & Company Profiles

The competitive landscape and company profile chapters of the market report are dedicated to the major players in the Preimplantation Genetic Testing market. An evaluation of these market players through their product benchmarking, key developments and financial statements sheds a light into the overall market evaluation. The company profile section also includes a SWOT analysis (top three companies) of these players. In addition, the companies that are provided in this section can be customized according to the clients requirements.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24037&utm_source=JLN&utm_medium=005

Preimplantation Genetic Testing Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Preimplantation Genetic Testing market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Preimplantation Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Preimplantation Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Preimplantation Genetic Testing Market, By Deployment Model

5.1 Overview

6 Preimplantation Genetic Testing Market, By Solution

6.1 Overview

7 Preimplantation Genetic Testing Market, By Vertical

7.1 Overview

8 Preimplantation Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Preimplantation Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.verifiedmarketresearch.com/product/Preimplantation-Genetic-Testing-Market/?utm_source=JLN&utm_medium=005

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Cellular Health Screening-Health Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Preimplantation Genetic Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Cell Based Assays Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Preimplantation Genetic Testing Market Growth Trends, Key Players, Competitive Strategies and Forecasts to 2026 - Jewish Life News

The research study Genetic Testing for Consumers (DTC) market 2020 launched by ABRReports.com provides the detailed analysis of the current market status, investment plans, production and consumption, price trends, and analysis by the market player, by region, by type, by application and etc, and custom research can be added according to specific requirements

Get Sample Copy of the report at https://www.abrreports.com/industry-insights/covid-19-impact-on-2020-2026-global-and-regional-genetic-testing-for-consumers-dtc-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version?form=request-report-sample

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth.

The key players covered in the Genetic Testing for Consumers (DTC) Market research report are:By Market Players:MapmygenomeMyHeritageFull Genome CorporationKarmagenesColor GenomicsHelix OpCo LLCIdentigeneEasy DNAFamilytreeDNA (Gene By Gene)Living DNAAncestryGenesis Healthcare23andMePathway Genomics

By TypeCarrier TestingPredictive TestingAncestry & Relationship TestingNutrigenomics TestingOthers

By ApplicationOnline PlatformsOver-the-Counter

Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/covid-19-impact-on-2020-2026-global-and-regional-genetic-testing-for-consumers-dtc-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version

The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

Key pointers of the Table of Contents:

Chapter 1 Industry OverviewChapter 2 Global Genetic Testing for Consumers (DTC) Competition by Types, Applications, and Top Regions and CountriesChapter 3 Production Market AnalysisChapter 4 Global Genetic Testing for Consumers (DTC) Sales, Consumption, Export, Import by Regions (2015-2020)Chapter 5 North America Genetic Testing for Consumers (DTC) Market AnalysisChapter 6 East Asia Genetic Testing for Consumers (DTC) Market AnalysisChapter 7 Europe Genetic Testing for Consumers (DTC) Market AnalysisChapter 8 South Asia Genetic Testing for Consumers (DTC) Market AnalysisChapter 9 Southeast Asia Genetic Testing for Consumers (DTC) Market AnalysisChapter 10 Middle East Genetic Testing for Consumers (DTC) Market AnalysisChapter 11 Africa Genetic Testing for Consumers (DTC) Market AnalysisChapter 12 Oceania Genetic Testing for Consumers (DTC) Market AnalysisChapter 13 South America Genetic Testing for Consumers (DTC) Market AnalysisChapter 14 Company Profiles and Key Figures in Genetic Testing for Consumers (DTC) BusinessChapter 15 Global Genetic Testing for Consumers (DTC) Market Forecast (2021-2026)Chapter 16 Conclusions

Purchase the research study @

https://www.abrreports.com/industry-insights/covid-19-impact-on-2020-2026-global-and-regional-genetic-testing-for-consumers-dtc-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version/checkout?option=one

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company that offers market research reports to individuals, organizations, and industries to enhance and strengthen the decision making process. With an associate thoroughgoing list of market research Publishers, we tend to cut across all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trends, information on products, regional market, and keen business insights to our clients.

Contact Us:

Scott HarrisSales ManagerEmail ID: [emailprotected]Phone No.: +1-561-448-7424

The rest is here:
Genetic Testing for Consumers (DTC) Market 2026 Growth Prospects, Key Trends, COVID-19 Business Impact and Future Scenario - Cole of Duty

Direct-Access Genetic Testing Market report has recently added by A2Z Market Research which helps to make informed business decisions. The comprehensive report on global Direct-Access Genetic Testing Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

Get Free Sample Copy of this Report: https://www.a2zmarketresearch.com/sample?reportId=265122

Top Key Players in profiled in this Market:

23andMe, MyHeritage, LabCorp, Myriad Genetics, Ancestry.com, Quest Diagnostics, Gene By Gene, DNA Diagnostics Center, Invitae, IntelliGenetics, Ambry Genetics, Living DNA, EasyDNA, Pathway Genomics, Centrillion Technology, Xcode, Color Genomics, Anglia DNA Services, African Ancestry, Canadian DNA Services, DNA Family Check, Alpha Biolaboratories, Test Me DNA, 23 Mofang, Genetic Health, DNA Services of America, Shuwen Health Sciences, Mapmygenome, Full GenomesThe key questions answered in this report:

The report offers a competitive situation analysis in the Direct-Access Genetic Testing market. The chapter competitive landscape from the report provides the revenue contribution of major market players along with their market share for the last four to five years. Further, a product comparison matrix and differentiating factors analysis are covered in the report. The strategic development analysis includes various recent initiatives taken by the market players such as product launches, partnerships, research initiatives, global expansions and acquisitions are analyzed in the market report. These developments help the readers of the report to make various decisions such as identifying the target customers, competitor product tracking, and strategy analysis to sustain in the competition.

Global Direct-Access Genetic Testing Market Segmentation:

Market Segmentation: By Type

Diagnostic ScreeningPGDRelationship testing

Market Segmentation: By Application

OnlineOffline

Get 20% Discount on First Purchase of this Report: https://www.a2zmarketresearch.com/discount?reportId=265122

The major growth drivers, challenges, and trends influencing the global Direct-Access Genetic Testing market are inspected at length. The report also presents a thorough qualitative and quantitative data affecting to the projected impact of these factors on markets future growth prospects. A number of analysis tools such as Porters five forces analysis and SWOT analysis have been employed to provide an accurate understanding of this market. Also, the report is compiled in a way for the readers and customers to understand better.

Global Direct-Access Genetic Testing Market report provide insights on following points:

Table of Contents

Global Direct-Access Genetic Testing Market Research Report 2020 2026

Chapter 1 Direct-Access Genetic Testing Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Direct-Access Genetic Testing Market Forecast

Have Query, Inquire Here: https://www.a2zmarketresearch.com/enquiry?reportId=265122

If you have any special requirements, please let us know and we will offer you the report as you want.

Read the original:
Direct-Access Genetic Testing Market Breaking New Grounds and Touch new Level in Upcoming Year by 23andMe, MyHeritage, LabCorp, Myriad Genetics,...

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Breast Cancer Predictive Genetic TestingMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Breast Cancer Predictive Genetic Testing Market Players to battle Covid-19 Impact.

The Breast Cancer Predictive Genetic TestingMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Breast Cancer Predictive Genetic Testing market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Breast Cancer Predictive Genetic Testing market.

Top Leading players covered in the Breast Cancer Predictive Genetic Testing market report: Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae and More

Get PDF Sample Report With Impact of COVID-19 on Breast Cancer Predictive Genetic Testing [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/78838

The report offers clear guidelines for players to cement a position of strength in the global Breast Cancer Predictive Genetic Testing market. It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Breast Cancer Predictive Genetic Testing market will showcase a steadyCAGR in the forecast year 2020 to 2026.

Market Segment by Type covers:High Penetrant GenesIntermediate Penetrant GenesLow Penetrant Genes

Market Segment by Application covers:HospitalsClinicsOthers

Our Complimentary Sample Breast Cancer Predictive Genetic Testing market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here!https://www.marketinforeports.com/Market-Reports/Request_discount/78838

Regions Covered in the Global Breast Cancer Predictive Genetic Testing Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Breast Cancer Predictive Genetic Testing Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2026 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Breast Cancer Predictive Genetic Testing market Exhaustive research on innovation and other trends of the global Breast Cancer Predictive Genetic Testing market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/78838/Breast-Cancer-Predictive-Genetic-Testing-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/78838/Breast-Cancer-Predictive-Genetic-Testing-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]Website: http://www.marketinforeports.com

More:
COVID-19 Update: Global Breast Cancer Predictive Genetic Testing Market is Expected to Grow at a Healthy CAGR with top players Roche, Thermo Fisher...

A new UK-Italian genomics alliance promises to leverage Cambridge artificial intelligence to transform cancer patient management, treatment and monitoring.

Cambridge Cancer Genomics (CCG.ai) has joined forces with Abruzzo-based Dante Labs, a pioneer and leader in genomic testing, and Birmingham business Nonacus which provides genetic testing products for precision medicine and liquid biopsy.

CCG.ai, a software developer specialising in data-driven precision oncology, says the partnership aims to build the most comprehensive and patient-centric tumour profiling service.

By combining Dante Labs experience and capacity in delivering a sequencing service for both solid tumour and cell free circulating tumour DNA from liquid biopsies, Nonacus sensitive targeted pan-cancer NGS libraries, and CCG.ais industry AI-powered software platform, OncOS, the companies will enable precision oncology at scale.

Improving outcomes for cancer patients means ensuring they have the right drug, at the right time to beat their cancer. This means understanding the molecular profile of the individual cancer and using that data to recommend treatments or clinical trials.

Oncologists and clinical researchers will be able to send samples for processing to Dante Labs, who will use library preparation kits from Nonacus and software from CCG.ai to create a sample to report solution.

If there are actionable mutations, the report will recommend the right treatments for those mutations; if there are novel or unactionable mutations the software will also be able to match possible clinical trials.

Nirmesh Patel, CSO at Cambridge Cancer Genomics, said: With cancer being one of the greatest healthcare challenges we are facing, this partnership opens the door to democratising access to data-driven cancer treatment.

Combining our industry leading precision oncology platform with Nonacus precise NGS solutions and Dante Labs fast and efficient NGS services provides customers with the ability to perform precision oncology at scale.

The combined solution will enable oncologists to precisely and comprehensively profile a patients tumour and ultimately improve outcomes.

Chris Sale, CEO of Nonacus, pointed out that COVID-19 had increased the backlog of genetic testing for cancer, potentially leaving many suspected cancers unconfirmed and treatments delayed.

He said: Long turn-around time and lack of clinically oriented analysis are the main obstacles to fully deliver the potential of cancer genomics to patients.

This partnership will provide the flexibility and accuracy that oncology professionals need to integrate cancer genomics into the care of their patients. Only by developing comprehensive content at scale will it be possible to address the COVID backlog.

Dr Mattia Capulli and Andrea Riposati of Dante Labs

Gianmarco Contino of Dante Labs described the venture as the beginning of a revolution in cancer treatment. Until now we have been treating cancer by tissue of origin.

But each cancer harbours a unique combination of mutation which makes it effectively a rare disease. Therefore the right approach should be to start from the mutations and look for the right drugs.

There is a great deal we can learn from sequencing cancer genomes: not only what therapy is going to be more effective but also safer and less toxic. We are now at a stage where a patient can benefit directly from this knowledge. Machine learning is helping us to unleash the potential of information hidden in the complexity of the genome.

See more here:
UK-Italy genomics venture to scale precision oncology - Business Weekly

LOS ANGELES, United States: QY Research has recently published a report, titled Global PCR-Based Testing Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global PCR-Based Testing market. It informs readers about key trends and opportunities in the global PCR-Based Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global PCR-Based Testing market.

Key companies operating in the global PCR-Based Testing market include Abbott, Bio-Rad, Bosch Healthcare, GenMark Diagnostics, GSK, Roche, MeMed, Micronics (Sony), Qorvo Biotechnologies, Siemens Healthineers, STMicroelectronics, Veredus Laboratories, Zoetis, Thermo Fisher, QIAGEN, Agilent, Bioer, Biosynex, Esco, Analytik Jena, Techne

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1836736/global-pcr-based-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global PCR-Based Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global PCR-Based Testing Market Segment By Type:

Analyzers/Instruments, Kits/Panels

Global PCR-Based Testing Market Segment By Application:

Diagnosis and Treatment Genetic Testing Cancer Evolutionary Biology Genetic Fingerprint Forensic Research COVID-19 Others Global PCR-Based Testing

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global PCR-Based Testing market.

Key companies operating in the global PCR-Based Testing market include Abbott, Bio-Rad, Bosch Healthcare, GenMark Diagnostics, GSK, Roche, MeMed, Micronics (Sony), Qorvo Biotechnologies, Siemens Healthineers, STMicroelectronics, Veredus Laboratories, Zoetis, Thermo Fisher, QIAGEN, Agilent, Bioer, Biosynex, Esco, Analytik Jena, Techne

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1836736/global-pcr-based-testing-market

TOC

1 Market Overview of PCR-Based Testing1.1 PCR-Based Testing Market Overview1.1.1 PCR-Based Testing Product Scope1.1.2 Market Status and Outlook1.2 Global PCR-Based Testing Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global PCR-Based Testing Market Size by Region (2015-2026)1.4 Global PCR-Based Testing Historic Market Size by Region (2015-2020)1.5 Global PCR-Based Testing Market Size Forecast by Region (2021-2026)1.6 Key Regions, PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.1 North America PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.2 Europe PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.3 Asia-Pacific PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.4 Latin America PCR-Based Testing Market Size YoY Growth (2015-2026)1.6.5 Middle East & Africa PCR-Based Testing Market Size YoY Growth (2015-2026) 2 PCR-Based Testing Market Overview by Type2.1 Global PCR-Based Testing Market Size by Type: 2015 VS 2020 VS 20262.2 Global PCR-Based Testing Historic Market Size by Type (2015-2020)2.3 Global PCR-Based Testing Forecasted Market Size by Type (2021-2026)2.4 Analyzers/Instruments2.5 Kits/Panels 3 PCR-Based Testing Market Overview by Application3.1 Global PCR-Based Testing Market Size by Application: 2015 VS 2020 VS 20263.2 Global PCR-Based Testing Historic Market Size by Application (2015-2020)3.3 Global PCR-Based Testing Forecasted Market Size by Application (2021-2026)3.4 Diagnosis and Treatment3.5 Genetic Testing3.6 Cancer3.7 Evolutionary Biology3.8 Genetic Fingerprint3.9 Forensic Research3.10 COVID-193.11 Others 4 Global PCR-Based Testing Competition Analysis by Players4.1 Global PCR-Based Testing Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PCR-Based Testing as of 2019)4.3 Date of Key Manufacturers Enter into PCR-Based Testing Market4.4 Global Top Players PCR-Based Testing Headquarters and Area Served4.5 Key Players PCR-Based Testing Product Solution and Service4.6 Competitive Status4.6.1 PCR-Based Testing Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Abbott5.1.1 Abbott Profile5.1.2 Abbott Main Business5.1.3 Abbott Products, Services and Solutions5.1.4 Abbott Revenue (US$ Million) & (2015-2020)5.1.5 Abbott Recent Developments5.2 Bio-Rad5.2.1 Bio-Rad Profile5.2.2 Bio-Rad Main Business and Companys Total Revenue5.2.3 Bio-Rad Products, Services and Solutions5.2.4 Bio-Rad Revenue (US$ Million) (2015-2020)5.2.5 Bio-Rad Recent Development and Reaction to Covid-195.3 Bosch Healthcare5.5.1 Bosch Healthcare Profile5.3.2 Bosch Healthcare Main Business5.3.3 Bosch Healthcare Products, Services and Solutions5.3.4 Bosch Healthcare Revenue (US$ Million) & (2015-2020)5.3.5 GenMark Diagnostics Recent Developments5.4 GenMark Diagnostics5.4.1 GenMark Diagnostics Profile5.4.2 GenMark Diagnostics Main Business5.4.3 GenMark Diagnostics Products, Services and Solutions5.4.4 GenMark Diagnostics Revenue (US$ Million) & (2015-2020)5.4.5 GenMark Diagnostics Recent Developments5.5 GSK5.5.1 GSK Profile5.5.2 GSK Main Business5.5.3 GSK Products, Services and Solutions5.5.4 GSK Revenue (US$ Million) & (2015-2020)5.5.5 GSK Recent Developments5.6 Roche5.6.1 Roche Profile5.6.2 Roche Main Business5.6.3 Roche Products, Services and Solutions5.6.4 Roche Revenue (US$ Million) & (2015-2020)5.6.5 Roche Recent Developments5.7 MeMed5.7.1 MeMed Profile5.7.2 MeMed Main Business and Companys Total Revenue5.7.3 MeMed Products, Services and Solutions5.7.4 MeMed Revenue (US$ Million) (2015-2020)5.7.5 MeMed Recent Development and Reaction to Covid-195.8 Micronics (Sony)5.8.1 Micronics (Sony) Profile5.8.2 Micronics (Sony) Main Business5.8.3 Micronics (Sony) Products, Services and Solutions5.8.4 Micronics (Sony) Revenue (US$ Million) & (2015-2020)5.8.5 Micronics (Sony) Recent Developments5.9 Qorvo Biotechnologies5.9.1 Qorvo Biotechnologies Profile5.9.2 Qorvo Biotechnologies Main Business5.9.3 Qorvo Biotechnologies Products, Services and Solutions5.9.4 Qorvo Biotechnologies Revenue (US$ Million) & (2015-2020)5.9.5 Qorvo Biotechnologies Recent Developments5.10 Siemens Healthineers5.10.1 Siemens Healthineers Profile5.10.2 Siemens Healthineers Main Business5.10.3 Siemens Healthineers Products, Services and Solutions5.10.4 Siemens Healthineers Revenue (US$ Million) & (2015-2020)5.10.5 Siemens Healthineers Recent Developments5.11 STMicroelectronics5.11.1 STMicroelectronics Profile5.11.2 STMicroelectronics Main Business5.11.3 STMicroelectronics Products, Services and Solutions5.11.4 STMicroelectronics Revenue (US$ Million) & (2015-2020)5.11.5 STMicroelectronics Recent Developments5.12 Veredus Laboratories5.12.1 Veredus Laboratories Profile5.12.2 Veredus Laboratories Main Business5.12.3 Veredus Laboratories Products, Services and Solutions5.12.4 Veredus Laboratories Revenue (US$ Million) & (2015-2020)5.12.5 Veredus Laboratories Recent Developments5.13 Zoetis5.13.1 Zoetis Profile5.13.2 Zoetis Main Business5.13.3 Zoetis Products, Services and Solutions5.13.4 Zoetis Revenue (US$ Million) & (2015-2020)5.13.5 Zoetis Recent Developments5.14 Thermo Fisher5.14.1 Thermo Fisher Profile5.14.2 Thermo Fisher Main Business5.14.3 Thermo Fisher Products, Services and Solutions5.14.4 Thermo Fisher Revenue (US$ Million) & (2015-2020)5.14.5 Thermo Fisher Recent Developments5.15 QIAGEN5.15.1 QIAGEN Profile5.15.2 QIAGEN Main Business5.15.3 QIAGEN Products, Services and Solutions5.15.4 QIAGEN Revenue (US$ Million) & (2015-2020)5.15.5 QIAGEN Recent Developments5.16 Agilent5.16.1 Agilent Profile5.16.2 Agilent Main Business and Companys Total Revenue5.16.3 Agilent Products, Services and Solutions5.16.4 Agilent Revenue (US$ Million) (2015-2020)5.16.5 Agilent Recent Development and Reaction to Covid-195.17 Bioer5.17.1 Bioer Profile5.17.2 Bioer Main Business5.17.3 Bioer Products, Services and Solutions5.17.4 Bioer Revenue (US$ Million) & (2015-2020)5.17.5 Bioer Recent Developments5.18 Biosynex5.18.1 Biosynex Profile5.18.2 Biosynex Main Business5.18.3 Biosynex Products, Services and Solutions5.18.4 Biosynex Revenue (US$ Million) & (2015-2020)5.18.5 Biosynex Recent Developments5.19 Esco5.19.1 Esco Profile5.19.2 Esco Main Business5.19.3 Esco Products, Services and Solutions5.19.4 Esco Revenue (US$ Million) & (2015-2020)5.19.5 Esco Recent Developments5.20 Analytik Jena5.20.1 Analytik Jena Profile5.20.2 Analytik Jena Main Business5.20.3 Analytik Jena Products, Services and Solutions5.20.4 Analytik Jena Revenue (US$ Million) & (2015-2020)5.20.5 Analytik Jena Recent Developments5.21 Techne5.21.1 Techne Profile5.21.2 Techne Main Business5.21.3 Techne Products, Services and Solutions5.21.4 Techne Revenue (US$ Million) & (2015-2020)5.21.5 Techne Recent Developments 6 North America6.1 North America PCR-Based Testing Market Size by Country6.2 United States6.3 Canada 7 Europe7.1 Europe PCR-Based Testing Market Size by Country7.2 Germany7.3 France7.4 U.K.7.5 Italy7.6 Russia7.7 Nordic7.8 Rest of Europe 8 Asia-Pacific8.1 Asia-Pacific PCR-Based Testing Market Size by Region8.2 China8.3 Japan8.4 South Korea8.5 Southeast Asia8.6 India8.7 Australia8.8 Rest of Asia-Pacific 9 Latin America9.1 Latin America PCR-Based Testing Market Size by Country9.2 Mexico9.3 Brazil9.4 Rest of Latin America 10 Middle East & Africa10.1 Middle East & Africa PCR-Based Testing Market Size by Country10.2 Turkey10.3 Saudi Arabia10.4 UAE10.5 Rest of Middle East & Africa 11 PCR-Based Testing Market Dynamics11.1 Industry Trends11.2 Market Drivers11.3 Market Challenges11.4 Market Restraints 12 Research Finding /Conclusion 13 Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Disclaimer13.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to see the original:
Trending: PCR-Based Testing Market Segmentation Along With Regional Outlook, Competitive Strategies, Factors Contributing To Growth 2020-2026| -...